GSK-LSD1 (hydrochloride)

Lysine-specific demethylase 1 (LSD1) belongs to the family of flavin adenine dinucleotide (FAD)-dependent amine oxidases that include monoamine oxidases (MAOs) and polyamine oxidase (PAO). LSD1 specifically demethylates mono- and dimethylated histone H3 lysine 4, resulting in transcriptional repression. It also controls the tumor suppressor activity of p53 by demethylating a specific p53 lysine residue (LYS370). GSK-LSD1 is an irreversible, mechanism-based inhibitor of LSD1 (IC50 = 16 nM) that is >1,000-fold selective over the closely related FAD-utilizing enzymes LSD2, MAO-A, and MAO-B. GSK-LSD1 induces gene expression changes in various cancer cell lines, inhibiting their proliferation (EC50s Structural Genomics Consortium (SGC) website for more information.Formal Name: rel-N-[(1R,2S)-2-phenylcyclopropyl]-4-piperidinamine, dihydrochloride. CAS Number: 2102933-95-7. Molecular Formula: C14H20N2 . 2HCl. Formula Weight: 289.2. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 1 mg/ml, DMSO: 25 mg/ml, Ethanol: 0.1 mg/ml, PBS (pH 7.2): 10 mg/ml. lambdamax: 211 nm. SMILES: [C@H]1(C2=CC=CC=C2)[C@H](NC3CCNCC3)C1.Cl.Cl. InChi Code: InChI=1S/C14H20N2.2ClH/c1-2-4-11(5-3-1)13-10-14(13)16-12-6-8-15-9-7-12,,/h1-5,12-16H,6-10H2,2*1H/t13-,14+,,/m0../s1. InChi Key: PJFZOGMSPBHPNS-WICJZZOFSA-N.